Drug Profile


Alternative Names: ABR-215050; TASQ

Latest Information Update: 13 Apr 2017

Price : $50

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Ipsen
  • Class Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Suspended Multiple myeloma
  • Discontinued Gastric cancer; Hepatocellular carcinoma; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 12 Apr 2017 Tasquinimod receives Orphan Drug status for Multiple myeloma in USA
  • 11 Nov 2016 Suspended - Preclinical for Multiple myeloma in Sweden (unspecified route) (9207246; Active Biotech pipeline, November 2016)
  • 23 Mar 2016 Tasquinimod is available for licensing as of 23 Mar 2016. http://www.activebiotech.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top